Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 for rare liver disease
Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but […]
Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but […]
GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for […]
Clinical tests of drugs from Gilead Sciences and Novo Nordisk have yielded encouraging results in nonalcoholic steatohepatitis (NASH), and the partners now want to see […]
Hanmi will retain options for the drug, efinopegdutide, in Korea under the deal, in which Merck is paying the Seoul-based company $10 million upfront and […]
The company is hoping to close its seed funding round in the next six months and aims to be in a position to seek regulatory […]
The company said it was formally terminating the Phase III study of the drug elafibranor in NASH and refocus its development of the drug on […]
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for […]
Copyright © 2024 | WordPress Theme by MH Themes